Aurobindo Pharma Limited has informed the Exchange regarding a press release dated Jun 03, 2026, titled "Aurobindo Pharma Inaugurates TheraNym - Pioneering India s Large-Scale Biologics Contract Manufacturing Facility".
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo Pharma has inaugurated a new large-scale biologics contract manufacturing facility called TheraNym. The company is positioning it as a pioneering setup for biologics contract manufacturing in India. No financial details, capacity numbers, or investment amount were disclosed in this filing. The move signals Aurobindo's strategic expansion into the biologics CDMO (Contract Development and Manufacturing Organization) space.
This is a strategic milestone that could expand Aurobindo's revenue streams through biologics contract manufacturing, but without disclosed capex or capacity figures, near-term financial impact remains unclear. Long-term, it diversifies the company beyond small-molecule generics into higher-margin biologics services.